Analysts Set Flex Pharma, Inc. (FLKS) PT at $17.50
Flex Pharma, Inc. (NASDAQ:FLKS) has earned an average rating of “Buy” from the six analysts that are currently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $17.50.
A number of research analysts have weighed in on the stock. Zacks Investment Research upgraded shares of Flex Pharma from a “sell” rating to a “hold” rating in a research note on Monday, August 7th. Jefferies Group LLC dropped their target price on shares of Flex Pharma from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, May 4th.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/25/analysts-set-flex-pharma-inc-flks-pt-at-17-50.html.
Hedge funds have recently made changes to their positions in the stock. LMR Partners LLP acquired a new stake in shares of Flex Pharma during the second quarter worth approximately $104,000. Bank of New York Mellon Corp boosted its stake in shares of Flex Pharma by 1.2% in the first quarter. Bank of New York Mellon Corp now owns 42,053 shares of the biotechnology company’s stock worth $185,000 after buying an additional 487 shares during the last quarter. Spark Investment Management LLC acquired a new stake in shares of Flex Pharma during the first quarter worth approximately $223,000. Royce & Associates LP boosted its stake in shares of Flex Pharma by 255.1% in the first quarter. Royce & Associates LP now owns 242,200 shares of the biotechnology company’s stock worth $1,066,000 after buying an additional 174,000 shares during the last quarter. Finally, C WorldWide Group Holding A S boosted its stake in shares of Flex Pharma by 11.2% in the first quarter. C WorldWide Group Holding A S now owns 278,060 shares of the biotechnology company’s stock worth $1,223,000 after buying an additional 28,060 shares during the last quarter. Institutional investors own 29.35% of the company’s stock.
Shares of Flex Pharma (NASDAQ FLKS) traded up 2.57% during trading on Tuesday, reaching $3.59. The company had a trading volume of 8,462 shares. The firm has a 50 day moving average price of $3.69 and a 200 day moving average price of $3.86. The company’s market cap is $62.05 million. Flex Pharma has a 12 month low of $3.01 and a 12 month high of $12.07.
Flex Pharma (NASDAQ:FLKS) last released its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.51) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.63) by $0.12. The firm had revenue of $0.34 million for the quarter, compared to analysts’ expectations of $0.46 million. Flex Pharma had a negative net margin of 2,410.97% and a negative return on equity of 64.15%. Analysts predict that Flex Pharma will post ($2.42) earnings per share for the current year.
Flex Pharma Company Profile
Flex Pharma, Inc is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms.
Receive News & Stock Ratings for Flex Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flex Pharma Inc. and related stocks with our FREE daily email newsletter.